1. Medtech Insight
  2. >>Device Area
  3. >>Diagnostics

GE And Roche Join Forces In First-Of-Its-Kind Tech Pact

 
• By Tina Tan

The goliaths of imaging and in vitro diagnostics have sealed a pact to codevelop a new data analytics platform for faster clinical decision-making, more accurate diagnosis and more personalized treatments.

GE Healthcare and Roche, the respective number ones in the diagnostic imaging and in vitro diagnostics markets, have agreed to codevelop a new, jointly branded software tool that will apply advanced analytics to in vivo data from GE's imaging and monitoring equipment and in vitro data from Roche’s biomarker, tissue pathology, genomics and sequencing portfolio.

The tool will allow for faster, more accurate and more confident decision-making, according to the companies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostic Imaging

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

‘AI Isn’t Flying Off The Shelves In The NHS,’ Says Healthtech Startup CEO

 
• By Natasha Barrow

Vendor exhaustion, insufficient clinical-grade evidence, and outdated risk management are some of the reasons the NHS is struggling to adopt AI. Haris Shuaib, CEO of Newton's Tree, shared his insights with the audience at the “Next Frontier of Medical AI” event held at DAC Beachcroft's London office on 23 April.

AdvaMed Unveils Its First ‘AI Roadmap’ To Help Lawmakers Navigate Regulating The Technology Through Rocky Times

 
• By Brian Bossetta

Members of AdvaMed’s digital health tech board of directors discussed the organization’s efforts to aid the Trump administration and Congress in answering AI policy questions, especially as companies deal with mounting regulatory uncertainty.

More from Diagnostics

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.